Jones Financial Companies
ALXN

Jones Financial Companies’s Alexion Pharmaceuticals ALXN Stock Holding History

Jones Financial Companies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-55
Closed -$10K – 673
2021
Q2 		$10K Hold
55
– – ﹤0.01% 475
2021
Q1 		$8K Hold
55
– – ﹤0.01% 565
2020
Q4 		$9K Buy
+55
New +$7.07K ﹤0.01% 448
2013
Q4 		– Sell
-112
Closed -$13K – 584
2013
Q3 		$13K Buy
+112
New +$12.3K ﹤0.01% 487

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Jones Financial Companies's ALXN Position: Q3 2021 in Review

Jones Financial Companies sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 55 shares — an estimated $10K sold.

Jones Financial Companies first reported a position in ALXN in Q3 2013 and held it in 4 quarters. The position peaked at $13K in Q3 2013. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jones Financial Companies reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jones Financial Companies sold 55 Alexion Pharmaceuticals shares in Q3 2021, an estimated $10K.
  • Jones Financial Companies first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 4 quarters.
  • Jones Financial Companies's Alexion Pharmaceuticals position peaked at $13K in Q3 2013.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jones Financial Companies's 13F filing for Q3 2021, filed 12 Nov 2021.